VIZ.AI

Dr. Chris Mansi (a neurosurgeon) and David Golan (a data scientist) met and realized that stroke patients were dying not because treatment did not exist, but because the detection-to-treatment pipeline was too slow.

A brain scan might sit in a radiology queue for hours while a patient's brain tissue dies. They built an AI that analyzes CT scans in real-time, detects strokes instantly, and sends an alert directly to the neurosurgeon's phone.

The FDA cleared Viz.ai's stroke detection AI in 2018 — it was one of the first AI-powered medical devices to receive FDA clearance.

SaaS subscription for hospitals and health systems. Hospitals pay an annual license fee per facility for access to Viz.ai's detection and coordination platform.

Revenue scales with hospital adoption and expansion into new disease areas. The value proposition is measurable: faster treatment, better outcomes, fewer malpractice claims.

Viz.ai Stroke Detection (LVO detection from CT scans). Viz.ai Pulmonary Embolism (PE detection).

Viz.ai Aortic Disease (aneurysm detection). Viz.ai Coordination Platform (alert and coordinate care teams).

Real-time AI analysis and specialist notification.

Clinical evidence-driven sales. Viz.ai grew by publishing peer-reviewed studies showing that its AI reduced time-to-treatment for stroke patients by 26+ minutes.

Hospitals that adopted Viz.ai saw measurably better outcomes, which drove word-of-mouth among hospital networks. The company expanded from stroke into pulmonary embolism, aortic disease, and other time-sensitive conditions.

Hospital procurement cycles are notoriously slow — getting a new technology into a hospital can take 12-18 months. Regulatory requirements for medical AI are complex and country-specific.

Competition from large medical imaging companies (GE, Siemens, Philips) adding AI features to their existing platforms.

Backed by Insight Partners, Tiger Global, GV (Google Ventures), and Kleiner Perkins. Insight Partners led the $100 million Series D in 2022.